This trial is conducted in Asia. This is a clinical trial investigating the effectiveness of using Biphasic Insulin Aspart 70/30 in two different treatment regiments for 6 months in subjects with type 2 diabetes, not well controlled on their current oral anti-diabetic drug therapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
321
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Novo Nordisk Investigational Site
Wuhan, Hubei, China
Change in HbA1c
Time frame: After 24 weeks of treatment
Adverse events
Weight change
Fasting blood glucose
Hypoglycaemic episodes
2-hour postprandial blood glucose
after 24 weeks of treatment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Novo Nordisk Investigational Site
Nanjing, Jiangsu, China
Novo Nordisk Investigational Site
Xi'an, Shaanxi, China
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Novo Nordisk Investigational Site
Tianjin, Tianjin Municipality, China